These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29788981)

  • 1. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
    Guo J; Jin J; Oya M; Uemura H; Takahashi S; Tatsugami K; Rha SY; Lee JL; Chung J; Lim HY; Wu HC; Chang YH; Azad A; Davis ID; Carrasco-Alfonso MJ; Nanua B; Han J; Ahmad Q; Motzer R
    J Hematol Oncol; 2018 May; 11(1):69. PubMed ID: 29788981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
    Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J
    BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
    Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
    J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
    N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).
    Lara PN; Villanueva L; Ibanez C; Erman M; Lee JL; Heinrich D; Lipatov ON; Gedye C; Gokmen E; Acevedo A; Semenov A; Park SH; Gafanov RA; Kose F; Jones M; Du X; Munteanu M; Perini R; Choueiri TK; Motzer RJ
    BMC Cancer; 2024 Jul; 23(Suppl 1):1253. PubMed ID: 39054430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
    Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.
    Sternberg CN; Motzer RJ; Hutson TE; Choueiri TK; Kollmannsberger C; Bjarnason GA; Paul Nathan ; Porta C; Grünwald V; Dezzani L; Han J; Tannir NM
    Clin Genitourin Cancer; 2019 Dec; 17(6):425-435.e4. PubMed ID: 31601514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
    Lai JS; Beaumont JL; Diaz J; Khan S; Cella D
    Cancer; 2016 Jan; 122(2):287-95. PubMed ID: 26457466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
    Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
    BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH; Park I; Lee JL
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
    Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
    Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care costs among renal cancer patients using pazopanib and sunitinib.
    Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
    J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
    Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
    Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
    Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
    J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
    Xu CF; Johnson T; Garcia-Donas J; Choueiri TK; Sternberg CN; Davis ID; Bing N; Deen KC; Xue Z; McCann L; Esteban E; Whittaker JC; Spraggs CF; Rodríguez-Antona C; Pandite LN; Motzer RJ
    Br J Cancer; 2015 Mar; 112(7):1190-8. PubMed ID: 25695485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
    Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
    Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
    Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
    J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
    Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
    BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience.
    Ekenel M; Karabulut S; Cil I; Zırtıloglu A; Aydın E; Tural D
    Actas Urol Esp (Engl Ed); 2020; 44(1):27-33. PubMed ID: 31744648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
    Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.